Rhythm Pharmaceuticals Inc. (RYTM) saw its stock price surge 9.84% during the pre-market session on Tuesday.
The significant move higher follows the company's release of its first quarter 2026 financial results, which exceeded analyst expectations. Rhythm Pharmaceuticals reported an EPS of $(0.83), beating the consensus estimate of $(0.84), while sales came in at $60.112 million, surpassing the $55.776 million forecast.